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IV. Malignant and Benign Neoplasm s of the Skin 
S kin cancers account for more t han half of all malignancies 
reported in the United S tates each year. Whereas deaths at-
tribu table to skin cancer are uncommon, the disability, disfig-
uremen t a nd cost associated wit h these lesions make skin cancer 
a major public health problem. 
Skin cancer is an excellent model for studying malignancies 
in general. T hese tumors develop in the body surface where 
they can be recogn ized and studied at an early stage; in some 
cases a "premalignant" phase is observed . Genetic suscept ibility 
is t h e cardinal endogenous predisposing factor, and chronic 
exposure to ul traviolet ligh t from the sun is the most frequen t 
exogen ous predisposing factor. A variety of chemicals is also 
carcinogenic to skin, and some of t hese are carcinogens for 
other o rgans as well. 
T h e skin develops a lymphoma, mycosis fungoides, which is 
of great interest as it is a proliferation of thymus-derived 
lymph ocytes, a cell type of major import in immunity. 
Alth ough viruses have not yet been shown to cause cancer of 
the skin in huma ns, a very common benign skin tumor, the 
wart, is due to a papilloma virus and can serve as a model for 
the study of viral-induced tumors of the skin. Because of the 
divergent nature of these disorders, t his report presents them 
in 3 sections. The first section discusses basal cell and squamous 
cell carcinomas aris ing fro m exposure to ult raviolet ligh t, chem-
icals, v iruses, a nd trauma. The second section deals with my-
cosis fu ngoides lymphoma. T he third considers t he study of 
wart disease as a model of viral oncogenesis . 
T h ere a.re a great many other malignan t a nd benign tumors 
of t h e human skin. These will not be considered here for the 
purpose of clarity and emphasis and because they occur less 
freq u e ntly or are of/ess medical concern. Malignan t melanomas 
are a very serious tumor and are covered in the section called 
"Melanoma a nd Vit iligo." 
1. BASAL CELL AND SQUAMOUS CELL CARCINOMAS 
Basal cell carcinoma is the most common human skin cancer 
that occurs in Caucasians. It is derived from epidermal a nd 
adnexal basal cells a nd frequently presents itself as a slow 
growing, shiny nodule composed of masses of cells with darkly 
staining nuclei t hat simula te epidermal basal cells. These le-
sions invade locally, but rarely metastasize. E xtensive epidemi-
ologic studies indicate t ha t these tumors ar e found primarily 
on the head and neck, that is, in sun-exposed areas. They are 
exceedingly rare in deeply pigmented races. There is a sta tisti-
cally significan t tendency for pa tients with basal cell carcinoma 
to have light eyes, ligh t ha ir and ligh t complexions, to sunburn 
easily, a nd to spend more hours outdoors tha n a con trol group 
of people without such tumors. They are more prevalent in 
geographic areas of high sun exposure. These findings support 
the complicity of sunlight in basal cell carcinoma formation, 
not however , to the exclusion of other factors. The actual 
distribution of this type of cancer on t he head and neck does 
not always correspond with sites of greatest UV exposure, i.e., 
they are concentra ted around the eye, behind the ear , and in 
other relatively protected sites. 
Squamous cell car cinoma is the second most common skin 
cancer in Caucasia ns and is found more often than basal cell 
epithelioma in t he pigmen ted races. It generally is a rela tively 
slow-growing keratotic tumor composed of masses of cells t hat 
simulate epidermal cells and tend to form keratin. H owever, 
the individual cells frequently show bizarre forms and shapes 
as well as malignant dyskeratosis. These lesions do metastasize 
at times. 
The e vidence for the par t icipation of sunlight in producing 
squamous cell carcinomas in Caucasians, albinos, and patients 
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wit h xeroderma pigmentosum is even more convincing than it 
is fo r producing basal cell epithelioma formatio n. T hese growths 
ar e distributed primarily over t he head a nd neck and, to a lesser 
extent, on the exposed areas of the upper extremit ies. They 
occur almost exclusively on anatomical sites that receive the 
maximal UV irradiation, such as t he r im of t he ear. Squamous 
cell carcinomas afflict t hose who work outdoors, are more 
prevalent in geographical areas of high sun exposure, and their 
incidence increases with decreasing latitude a nd increasing sun 
exposul'e. 
T hese lesions are uncommon in t he more deeply pigmented 
races. When they do occur, t hey are found primarily on the 
lower extremit ies and abdomen. T heir location corresponds to 
sites of chronic irritation and inj ury, rather than to sites of solar 
damage. 
Prevalence and Severity 
E ffec ts on quality of life. T he enumeration of skin cancer 
incidence in a population is made very difficult by the relative 
benigni ty of the disease and the curative treatment that takes 
place in physicians ' offices rather tha n in hospitals. Surveying 
all physicians in anyone area is difficul t and expensive; con-
sequently most skin cancer incidence studies have seriously 
underestimated actual conditions. 
P robably the most intense a nd accurate surveys have been 
those of Scotto (T hird National Cancer Survey, N ational Can-
cer Institute, 1971-72) and of McDonald (Texas only, 1960- 70). 
In both those surveys and in data fro m other studies, an inverse 
relationship with latitude is apparent. T he T hird Cancer Survey 
shows that the annual incidence rates for skin cancer (excluding 
maligna nt melanoma) vary from 379/ 100,000 in Dallas-Fort 
Worth (latitude 32.8 N) to 124/ 100,000 in Iowa (latitude 42 N) . 
Scotto et al measured t he flu x of ultraviolet ligh t in various 
locations and documented increasing UV flux with decreasing 
latitude. 
S kin cancer, like most forms of cancer, is a disease t hat occurs 
more freq uently in older age groups. However, unlike other 
types of cancer, the rates for skin cancer are significantly higher 
in the middle age groups, i.e., 35-54 years. 
Comparison of the earlier a nd more recent studies strongly 
suggests that skin cancer has increased in t he past several 
decades. For instance; in t he metropolitan a reas of Minnesota, 
an apparent 2-fold increase has occurred since 1963. T his is 
perhaps a reflection of the recent trend for many people to 
expose more of themselves for longer periods of time to the 
sun 's rays. 
T he best estimate for present annual incidence of nonmela-
noma skin cancer in Caucasians in the U.S. is 165/ 100,000 
population. T his means t hat about 300,000 cases of skin cancer 
develop in Caucasians in the U.S. each year, or about one-third 
to one-half of all cancers of all sites arise in the skin. It is indeed 
for tunate that the cure rate for skin cancer exceeds 95%. 
Estimates of annual costs. T he most recent, and probably 
the only reasona bly accurate, estimate of t he cost of medical 
care a nd t ime lost from work due to cancer of the skin was 
reported in 1975 as part of t he Climatic Impact Assessment 
Program. 
Table 4.1.18 of the Cl AP Monograph #6 estimates the eco-
nomic cost of skin cancer in 1971 dollars. Assumption II B 
assigns medical costs for nonmela nomic skin cancer at $125 and 
work-loss costs at $190, a total cost of $315 per cancer. For a 
minimum annual incidence rate of 300,000 cases, the annual 
cost (in 1971 dollars) is 94.5 million . A 60% inflation factor from 
1971 to 1977 adjusts the cost to more t han 150 mill ion in 1977 
dollars. 
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Assumption I in table 4.1.18 of ClAP monograph #6 assigns 
medical costs for malignant melanoma at $632, work-loss costs 
at $660, total cost of $1292 for each case. At the assumed 
incidence of 7,000 cases of malignant melanoma, the annual 
cost is 8.6 million 1971 dollars per year for malignant melanoma, 
or 13.76 million 1977 dollars. 
Thus a bare-bones estimate for annual costs for all skin 
cancer for 1977 is 164 million per year in medical and work loss 
costs. 
Preventi0'1., Treatment, and Cure 
Since non melanoma skin cancer has a cure rate of 95% or 
better, major reductions in future cost will come from preven-
tion. It is probable that the large majority of skin cancer is 
preventable. Better understanding of the interaction of the 
genetically susceptible population and causative environmental 
factors should bring about major strides in prevention. 
Status of Research 
Effects of ultraviolet (UV) light. The sun's role in the pro-
duction of human skin cancers does not lend itself to direct 
experimentation. However, many observations strongly suggest 
that sunlight induces these tumors. Briefly, the arguments to 
support such a hypothesis follows: 
1. It is clearly established that superficial skin cancers occur 
most frequently on parts of the body habitually exposed to 
sunlight: the head, neck, arms, and hands. 
2. Pigmented races sunburn much less readily than people 
with white skin and suffer much less skin cancer. When cancer 
does occur, it affects areas seldom exposed to sunlight. 
3. Among Caucasians there appears to be a much greater 
incidence of skin cancer in outdoor workers than in indoor 
workers. 
4. Skin cancer is more ·common in those white-skinned people 
who live in areas where there is a high UV flux. 
5. People with genetic diseases, such as albinism and xero-
derma pigmentosum, in whom the effects of solar UV radiation 
are exacerbated, develop skin cancer prematurely and at a 
greater rate than normal subjects. 
6. Superficial skin cancers, particularly squamous cell carci-
noma, occur predominantly on areas that receive maximum 
amounts of solar UV and show maximum histologic evidence of 
chronic UV damage. 
7. Skin cancer can be produced readily on the skin of mice 
and rats with repeated doses of UV radiation at the upper 
wavelength limit of 320 nm, the same spectral range that 
produces erythema solare in human skin. 
Although these arguments do not constitute proof, there is 
compelling epidemiologic evidence to support involvement of 
sunlight in the 3 types of skin cancers: basal cell carcinomas, 
squamous cell carcinomas, and malignant melanomas. In the 
light of such evidence, concern must be expressed over anything 
that increases the amount of ultraviolet light reaching Earth, 
such as that occasioned by the reduction of stratospheric ozone, 
the major ftltering agent of ultraviolet light, by the rise of oxides 
of nitrogen and fluorochloromethanes. 
Immunological mechanisms. Although the major effect of 
UV is to damage epidermal cell DNA and thus cause skin 
cancer, it has other damaging effects that might contribute to 
carcinogenesis. Thymus-dependent cellular immune recogni-
tion of tumors is suppressed in syngeneic mice following UV 
exposure. Immunological suppression or insufficiency allows 
the development of increased numbers of cancers of the skin 
and of other organs. Both a lymphoid cell factor and a serum 
factor can be induced in mice with ultraviolet light irradiation 
and these factors may actively interfere with tumor rejection 
by the normal lymphocytes. The relevance of these observa-
tions to human carcinogenesis by ultraviolet light is yet to be 
determined. 
Although immunotherapy has been an active area for inves-
tigation in treatment of systemic malignancies, it has been 
underemphasized in skin cancer research despite its promise 
·from early reports on the use of dinitrochlorobenzene (DNCB) 
on plaque and tumor stage mycosis fungoides and epithelial 
skin cancers. Promise of a future rational approach to the 
therapy of delayed-type hypersensitivity mechanisms in skin 
cancers has been brought about by significant advances in our 
understanding of contact sensitivity. Use of DNCB treatment 
of extensive skin cancers is still under an investigational new-
drug (IND) protocol. It appears to be as effective as the already 
approved cytostatic agent 5-fluorouracil (5FU). As 5FU is a 
sensitizing agent in addition to its cytostatic properties, some of 
its beneficial effects could be on the immune system. Regardless 
of the exact mechanism whereby contact sensitizers induce 
involution of epithelial neoplasms, the area warrants further 
investigation not only to develop practical approaches to the 
control of skin cancer, but also to extend principles discovered 
thereby to the treatment of systemic malignancies. 
Chemicals and trauma. The clinical observation that certain 
chemicals cause skin cancer led to their use as a laboratory tool 
for the study of the biological and biochemical mechanisms of 
cancer formation and as an animal test system to identify 
environmental carcinogens. From clinical, epidemiological, and 
research observations a number of chemicals have been recog-
nized as carcinogens. Some carcinogens, such as polycyclic 
aromatic hydrocarbons, aromatic azo dyes, alkylating agents, 
and nitrosamines, arise from industrial activity; some, such as 
cigarette smoke, from human activity; some, such as safarole, 
afl'atoxins, pyrrolizidine alkaloids, and cycasin, are naturally 
occurring plant and microorganism products; and some, such 
as asbestos and certain forms of beryllium, cadmium, zinc 
chromium, nickel, and arsenic, are inorganic material. ' 
The hazards of exposure to carcinogenic chemicals, largely 
encountered in occupations, have been reduced through im-
proved industrial hygiene. Even so, the risk is by no means 
eliminated. Since the most obvious remedies have already been 
applied in the United States, elimination of the residual risk 
may be considerably more difficult (expensive retooling for 
"clean" manufacturing processes; definition of susceptible suh-
populations of workers; development of methods for detection 
and prophylactic treatment of preclinical cancers, identification 
of as yet unrecognized carcinogens). The cost of these measures 
might far exceed the present level of direct medical costs to 
patients for skin cancer therapy. 
Chemicals as etiologic agents in skin cancer should alert 
society to the risks workers may be asked to take in our 
industrial age. UV radiation as etiologic agent in a highly visible 
form has alerted man to the hazards inherent in his interaction 
with environment. Similarly, chemically induced skin cancers 
are early warning signals and imply the possibility of similar 
long-term effects of chemicals at internal sites. 
Skin cancer secondary to burns and other trauma, although 
extremely low in incidence, may be expected to increase in the 
wake of improved therapy for burn patients who, in the past, 
would have died. Our basic understanding of the biologic events 
leading up to skin cancer formation in scars, especially from 
burns, is extremely scanty. It should be noted that an animal 
model, described some years ago, has never been fully exploited. 
Clinical recognition and understanding of chemically induced 
skin cancer represent defmite advances, as exemplified by the 
study of arsenical skin cancers. Various demographic and epi-
demiologic studies have proved that inorganic arsenic is a 
carcinogen for human skin. Unlike all other known human 
carcinogens and despite concerted efforts in many laboratories 
to induce a cancer by arsenic, no animal system has as yet 
demonstrated arsenic as a carcinogen. Newer in vitro tech-
niques may unravel this mystery. In studies on the mutagenic 
effects of chemicals, in which arsenic was added to the in vitro 
assays, significant abnormalities showed up. 
Animal models and mechanisms of cutaneous carcinogene-
sis. The skin has long been the target for study of the induction 
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of cancer in experimental animals by chemicals, radiation, and 
viruses. Both epidemiological surveys and animal studies have 
provided evidence that some chemicals in our environment are 
responsible for a significant proportion of human cancers, of 
which there are 2 major classes: (1) direct acting carcinogens 
and (2) indirect carcinogens that require metabolic activation 
by cells. Most carcinogens are of the second type. 
Chemical carcinogenesis is a multistep process. One of the 
best-studied models is the 2-stage carcinogenesis system in 
which mouse skin is used. Mouse skin tumors can be induced 
by the sequential application of a subthreshold dose of a carcin-
ogen (initiation phase) followed by repeated treatments with a 
noncarcinogenic tumor promoter (promotion phase). The ini-
tiation phase, essentially irreversible, requires but a single ap-
} plication of either a direct or indirect carcinogen. The promo-
tion phase, initially reversible, later becomes irreversible. The 
mouse skin system has been a key model for studying carcino-
genesis, for assaying carcinogenic agents, and for investigating 
the effects of inhibitors of chemical carcinogenesis. 
Recently, multistage carcinogenesis has been shown to be 
COIlllI1on to a number of other organs and systems: the liver, 
lung, bladder, colon, esophagus, mammary glands, and cell 
cultures. There are many factors that can modulate the effects 
of chemical carcinogenesis: genetic constitution, sex, age, diet 
and nutrition, hormones, immunology, trauma, viruses, radia-
tion, metabolism and detoxification of carcinogens, and the 
status of DNA repair systems. Anti-inflammatory steroids, re-
tinoids, protease inhibitors, antioxidants, and vitamins are some 
of the more important chemical agents that inhibit chemical 
carcinogenesis. 
The irreversible tumor initiation phase probably involves a 
somatic cell mutation as there is correlation of the potency of 
a chemical carcinogen and its mutagenic activity. Most tumor 
initiating agents either generate or are metabolically converted 
to electrophilic reactants that bind covalently to cellular DNA 
and other macromolecules. Correlation of the carcinogenicity 
of several polycyclic hydrocarbons and their ability to bind 
covalently to DNA has been demonstrated. The mouse skin 2-
I stage tumorigenesis system has been a prime model in showing 
that the "bay region" diol epoxide is the ultimate carcinogenic 
form of polycyclic hydrocarbon carcinogens that react with 
DNA. 
A significant general theory to explain the initial event in 
chemical carcinogenesis is that all chemical carcinogens that 
are not electrophilic reactants must be converted metabolically 
I into a chemically reactive electrophilic form which then reacts 
with some critical macromolecule to initiate the carcinogenic 
process. The DNA repair system is the cardinal determinant of 
whether or not the carcinogenic process is initiated in the cell; 
obviously this is a signal area for future research. 
The phorbol-ester-tumor-promoters are the most potent of 
the known tumor-promoters. They have many cellular and 
biochemical effects, some of which seem to be intimately asso-
ciated with the phorbol-ester-tumor-promoter's action. 
1. They induce changes in the phenotype of normal cells that 
mimic features of transformed cells. 
2. They induce adult epidermal cells to dedifferentiate so 
that they look like embryonic cells. 
3. They induce a 200-400 fold increase in epidermal ornithine 
decarboxylase activity; this enzyme specifically correlates with 
tumor promotion. 
4. They induce protease activity. 
5. They stimulate phospholipid, DNA, RNA and protein 
synthesis. 
6. They stimulate the cells to proliferate. 
7. They inhibit terminal differentiation not only in the skin 
but also in other cellular systems, such as Friend erythroleu-
I kemic cells, chicken myoblasts, and neuroblastoma cells. 
The effects of potential inhibitors on both the initiation and 
the promotion phases can be studied in the 2-stage animal skin 
tumorigenesis system. Many compounds have the capacity to 
inhibit the initiation of tumors. They act by altering the metab-
olism of the carcinogen by decreasing activation, by increasing 
detoxification, by "scavenging" active carcinogen molecules to 
prevent their reaching critical target sites in the cells, or by 
competitive inhibition. A number of other compounds inhibit 
the progression of cancer by altering the state of differentiation, 
by inhibiting the promoter-induced cellular proliferation, or by 
preventing gene activation by the tumor promoters. Table I 
summarizes the potent inhibitors of skin tumor initiation in 
mice by various chemical carcinogens. 
Some of the flavones and antioxidants appear to inhibit 
carcinogenesis by averting metabolic conversion of the carcin-
ogen to an ultimate carcinogenic molecular form. Noncarcino-
genic polycyclic hydrocarbons and environmental contaminants 
appear to inhibit skin carcinogenesis by inducing the detoxifi-
cation of carcinogens. Sulfur mustard suppresses tumor initia-
tion by actually killing the initiated cells. Certain retinoids are 
potent inhibitors of lung, mammary, bladder, and colon carci-
nogenesis and skin tumor promotion. It appears that their 
ability to thwart phorbol-ester-induced epidermal ornithine 
decarboxylase activity as it combines with their effect on epi-
thelial differentiation produces the anticarcinogenesis. The 
phorbol-ester-tumor-promoters which induce cellular prolifer-
ation and gene activation are inhibited in mice by retinoids, 
anti-inflammatory steroids such as dexamethasone, and pro-
tease inhibitors. 
Recent results suggest that certain flavones (5,6-benzoflavone 
and quercetin), antioxidants (BHA, selenium and Vitamins C 
and E), noncarcinogenic hydrocarbons, anti-inflammatory ste-
roids, and retinoids may be useful chemical agents for preven-
tion of cancer in man. 
Ionizing radiation comprises electromagnetic types (x-rays 
and y-rays) and particulate types (electrons, protons, neutrons, 
a-particles, and heavy nuclei). The biologic effects of both types 
ru'e the result of the ionization of cell constituents (priq1arily 
cellulal' macromolecules) and the formation of highly reactive 
free radicals. DNA strand breakage is linearly related to dosage. 
A single long exposure to ionizing radiation produces more skin 
tumors than fractionated exposures. 
There are several reports of studies of 2-stage carcinogenesis 
in which radiation (ionizing or UV light) was the tu'mor initiator 
and croton oil or phorbol esters the promoter. Similar studies 
have been performed in fibroblastic cells in culture. 
DNA viruses are responsible for some naturally occurring 
benign papillomas in man and rabbits. The RNA tumor viruses 
are responsible for the natural leukemia-sarcoma complexes of 
chickens and mice and for hormone-dependent carcinoma. Both 
kinds of viruses can produce malignant transformation in cul-
tured cells. Papillomas experimentally produced in rabbits by 
the Shope virus can become malignant. That the transforming 
effect of viruses on cultured cells is direct is indicated by the 
promptness with which transformation takes place and by the 
linear dose-response characteristic. The nucleic acid core of 
DNA viruses can also produce transformation. 
Culture of epidermal tumor cells. In 1975 it was reported 
that normal human epidermal keratinocytes could form 'colo-
nies from single stru·tel" cells and be serially transferred for 
many generations, provided that they were cultured with a 
lethally irradiated feeder layer of connective tissue fibroblas ts. 
TABLE 1. Inhibitors of shin tumor initiation in mice 
1. Antioxidants: butylated hydroxy toluene (BHT), butylated hydrox-
yanisole (BRA), and selenium 
2. Flavones: 7,8-benzoflavone, 5,6-benzoflavone, and quercetin 
3. Vitamins: A, C, and E 
4. Certain noncarcinogenic polycylcic hydrocarbons: dibenz-
(a,c)anthracene, benz(a)anthracene, benzo(e)pyrene, and pyrene 
5. Environmental contaminants: 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD) and polychlorobiphenyl (PCB) 
6. Sulfur mustru'd 
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Because large cultures can be started from small biopsies, 
karyological, ultrastructural, and biochemical analyses of epi-
dermal tumors are now feasible. Malignant cells may exhibit 
distinguished phenotypes in culture; these phenotypes could be 
used to diagnose lesions with uncertain histology. Fundamental 
studies could be made of the types of alteration that result in 
malignancy in this cell type. 
Thus far, epidermal cells cultured on glass or tissue culture 
plastic have failed to show the degree of stratification and 
development of granular and cornified layers that epidermal 
tissues do in vivo. Cells grown on plastic, however, continue to 
produce much keratin protein and retain their capacity for 
cornified cell envelope formation. Short-term organ culture of 
full thickness skin has been the necessary method for study of 
the control of some features of epidermal differentiation. A 
promising alternative to this use of unseparated dermal and 
epidermal components in organ culture is the recently reported 
successful use of the dermal collagen surface of sterile, dead 
pigskin as a substratum for keratinocyte growth. These cultures 
stratify extensively and form more normal granular and corni-
fied layers than those of other methods. 
Epidermal tumor systems to study epithelial cancer. The 
mouse has been used as a complete experimental system for 
study of epidermal carcinogenesis. A cell's behavior after cul-
tivation, drug treatment, carcinogenesis, selection, etc., in vitro 
can be tested in vivo. Primary cultures of mouse epidermal 
keratinocytes have been transformed chemically and reinocu-
lated subcutaneously into syngeneic animals to form tumors. A 
sophisticated implantation capsule has been developed to per-
mit the reformation of epidermis from normal or transformed 
cells after cultivation in vitro. The use of similar methods with 
the nude mouse for assaying invasive or metastatic behavior of 
cultured human epidermal cells could be the final step in 
meeting the requirements before undertaking a full experimen-
tal human system for the study of epidermal cancer. 
The histopathology and proliferative behavior of human 
epidermal tumors has been more completely characterized than 
that of any other epithelial tissue because of the skin 's external 
location and the frequency of epidermal neoplasia. The epider-
mal keratinocyte is the only human epithelial cell for which 
methods for in vitro studies of carcinogenesis and the malignant 
state have been developed. Since epithelial cancer accounts for 
90% of all human cancers, the human epidermis is recom-
mended as a practical model for study of the general problem 
of epithelial cancer. 
Needs for Additional Basic Research 
Ultraviolet light. We do not fully understand the central 
relationship of exposure to ultraviolet radiation and the subse-
quent development of skin cancer. Well-controlled studies are 
needed to determine what UV wave-lengths are responsible for 
inducing skin cancer in mice. These will be expensive and time 
consuming but very important projects in unraveling mecha-
nisms of skin cancer induction. Several types of exposure should 
be studied including multiple low doses of UV radiation and 
single large doses of UV radiation. In addition, studies are 
required on how the synergism of UV-B and the rest of the 
solar spectrum affects skin tumor development. These experi-
ments aJ'e particularly pertinent since continued destruction of 
the stratospheric ozone layer, which we can surely expect, will 
affect only UV-B; experiments have already shown that an 
interaction does exist. These experiments could be carried out 
by removing with fllters spectral bands from polychromatic 
beams of radiation. 
Investigation on how the magnitude of UV -B flux affects skin 
carcinogenesis is needed. Preliminary experiments have shown 
that total UV dose is not the only important factor: prolonged, 
lower flux levels seem to be more carcinogenic than short, high 
flux levels. 
The effect of varying the length of the intervals between 
exposures during carcinogenesis experiments should be studied. 
There are data that indicate that the length of the intervals 
between exposures may be critical in skin carcinogenesis. These 
experiments may be some of the most useful since future 
changes in the ozone layer, although they will affect the flux 
and spectral distribution of ultraviolet radiation, will not affect 
the length of time people will be exposed and the length of 
intervals between exposures. 
Mechanisms of carcinogenesis. It is known that errors made 
in the repair of damaged DNA will result in mutations, and a 
considerable amount of evidence is accumulating to support the 
concept that mutagenesis is the molecular basis of carcinogen-
esis. Our insights into DNA repair and mutagenesis have come 
from studies on bacteria mainly because strains deficient in 
different repair pathways are readily available. Basic studies on 
bacterial mutagenesis should be continued because they have 
provided and should continue to provide new techniques for 
similar experiments and further insights into mammalian cells. 
Mammalian cells showing altered DNA repair and mutation 
frequencies are now available (i.e., xeroderma pigmentosum). 
Considerable basic research remains undone upon these known 
cell lines and many more mammalian cell lines defective in 
other aspects of DNA repair need to be isolated and studied 
before our knowledge about mammalian DNA repair will ap-
proach that of bacterial repair. Current tests for capacity of 
mammalian cells to repair themselves need improvement and 
standardization. When this is achieved there should be a sys-
tematic search for and study of the repair capacity of skin cells 
taken from patients who show unusual sensitivity to light alone 
and to light in the presence of photosensitizing agents. Addi-
tionally, there is a need for study of the immunosuppressive 
effects of UV radiation in animals. 
Laboratory models. The animal skin model for carcinogene-
sis continues to be the most productive organ system to study 
how a normal cell changes to a cancerous cell. Rational ap-
proaches for prevention and control of cancers are now being 
developed with the multistage animal model and should receive 
increasing emphasis. This multistage model is ideal for studying 
the effects of many factors that modify carcinogenesis. The 
importance of discovering how these factors modify carcinogen-
esis cannot be overemphasized. Intensified research in this area 
will increase our understanding of carcinogenic mechanisms 
and hasten the application of anti carcinogenic agents to the 
prevention of human cancers. 
l. Genetic studies in which animals are bred for susceptibility 
and resistance to skin cancer should be pursued. 
2. Some important findings on the role of nutrition in carci-
nogenesis have come about through the use of the animal skin 
model. These studies need continued support. 
3. Viruses, radiation, and chemicals make the skin system 
susceptible to carcinogenesis. The interrelationship of these 
diverse causative agents can then best be studied in skin. 
We can now grow epithelial cells from man and mouse in 
culture. The culture system is excellent for investigation of 
various causative and protective agents in mouse and human 
cells. Studies on carcinogenesis in these cultured cells has begun 
and must continue. Collaboration of clinicians and research 
scientists inust be encouraged in the use of human epidermis as 
a model system. 
Needs for Additional Clinical Research 
UV technology. Support is needed to monitor the amount of 
UV radiation that reaches the earth . Monitor stations would 
establish baseline levels, discover the range of natural variation, 
note persistent changes outside the natural variation patterns. 
The development of ultraviolet radiation monitors for indi-
vidual use is also needed. These monitors should be used in 
field studies on the relationship of UV exposure and carcino-
genesis in large populations. The amount of daily ultraviolet 
radiation actually received by human skin must vary greatly 
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with occupation, behavior, and local climatic conditions. We 
know little about occupational UV exposure, and this impairs 
our ability to interpret existing data that relate UV exposure to 
skin cancer, to chronic skin disease, and to eye damage. Popu-
lation studies with personal monitors of UV-B radiation (such 
as the KPR type already studied in Switzerland) are needed to 
determine what fraction of UV radiation that strikes the ground 
is actually received by the skin surface, especially in persons at 
high risk of developing skin cancer. 
Our uncertainty of the width of the carcinogenic UV spec-
trum makes it difficult to apply data from ultraviolet radiation 
field measurement to projections of skin cancer incidence. Sup-
port must be given to the development of high intensity ultra-
violet radiation sources with both narrow (monochromatic) and 
.. wide (solar simulator) spectra. The UV carcinogenic spectrum 
seem to be the same as the erythema spectrum; however, the 
fine structure of the carcinogenic spectrum is not known. The 
unavailability of high intensity, narrow band ultraviolet sources 
that can irradiate areas as large as the skin surface of one mouse 
is the major obstacle. We need to develop powerful, tunable, 
continuous ultraviolet lasers; or we could use the ultraviolet 
radiation produced by the Stanford linear accelerator. The 
powerful solar simulators that have been developed for space 
application have been too expensive to use for 1- and 2-year 
animal experiments. Support is needed either to make them 
available or to develop less expensive but as effective simula-
tors. 
Epidemiology. Epidemiological study is particularly needed 
in 2 major areas: (1) the prevalence of non melanoma skin cancer 
and (2) identification of populations at risk. 
1. A program is needed to gather epidemiological data on 
prevalence of nonmelanoma skin cancer over a wide span of 
latitudes. Incidence data are extremely difficult to obtain ac-
curately; therefore, the prevalence data should be obtained 
first . Study areas should be separated by at least 300 miles 
north-south over a latitude span reaching beyond the most 
populated areas. Data obtained should include age at first 
tumor, sex, occupation, skin phenotype, and an estimate of 
daily solar UV-dose (obtained with the use of personal dosim-
eters). These studies should be controlled and coordinated with 
the same protocol so that valid comparisons can be made. 
Promising areas for such studies, in addition to the United 
States, are Australia (particularly Queensland), Scandanavia, 
and South Africa. . 
2. A program is needed through which the populations at 
greatest risk can be identified. Available evidence on prevalence 
and incidence of skin cancer suggest that persons with fair skin, 
light eyes, and freckles, who burn easily and tan poorly are at 
greater risk to develop skin cancer than others, and that this is 
a genetic (Celtic) trait. Efforts should be made to develop 
simple screening methods to identify the most susceptible 
among the population. UV -A photography and skin testing 
with solar simulators are promising for this purpose. 
Therapy. It is important to develop and improve topical and 
systemic agents to filter out the UV action spectrum from the 
light entering the skin. 
Immunotherapy, an active area for investigation in the treat-
ment of systemic malignancies, has been underemphasized in 
the treatment of skin cancer. Further studies should be sup-
ported on the efficacy of immunotherapy for both treatment 
and prevention of cutaneous neoplasms. 
2. MYCOSIS FUNGOIDES LYMPHOMA 
Prevalence and Severity 
Mycosis fungoides (MF) is an uncommon malignant lym-
phoma that appears to arise in the skin and eventually spreads 
into other organ systems. It is nosologically related to other 
malignant Iymphoproliferative disorders such as Hodgkin's dis-
ease (initial manifestations in lymph nodes) and leukemia (ini-
tial manifestations in bone marrow), and like these disorders 
will eventuate in premature death of a patient unless effective 
treatment is instituted. It progresses into a disfiguring, deform-
ing, disruptive, ugly, putrid disease that gradually destroys 
social and sexual contacts, and finally life itself, eroding to zero 
in many instances the patient's life savings and that of his or 
her family as well. Since the initial skin manifestations of MF 
are somewhat nonspecific, many cases are classified as poikilo-
derma, parapsoriasis, or other "benign" dermatoses and may be 
classified for years before the more appropriate histologic di-
agnosis is established. However, from the time of histologic 
diagnosis the median survival of patients with MF is less than 
5 years. Thus, the impact of the disease on the duration of life 
is somewhat variable; it is ultimately fatal for most patients. 
Although mycosis fungoides may develop in young adults, 
most cases begin in the fifth decade of life. It is estimated that 
1000-2000 new cases of MF develop each year in the United 
States; for unknown reasons, males predominate over females 
by about a 2:1 ratio. The disease occurs in all races. Epidemio-
logic evidence that MF patients employed in manufacturing or 
construction industries may survive for less time than others 
suggests that occupation may be a determining factor in the 
severity of the disease. The occurrence of the disease in close 
family members has been reported; a genetic predisposition to 
the disease, however, seems to be of low order. 
Effects on quality of life. Patients who suffer from MF are 
usually in good general health during the early intracutaneous 
phases of the disease. At this time disability is largely deter-
mined by the extent of involvement of the skin, and this ranges 
from a few localized lesions to diffuse, generalized involvement. 
Patients may experience marked pruritus, painful fissuring, 
tumor ulcerations, superficial bacterial infections, chills and 
fever, scaling, hair loss, and emotional distress, circumstances 
that impose functional limitations. Later the cutaneous seque-
lae are joined by wasting, systemic infections of diverse types, 
impairment of other organ systems, and death. Thus, the impact 
of this disease on the patient's life is substantial. 
Estimates of annual cost. Specific data are not available on 
the economic impact of MF. The lifetime cost of an average 
terminal case (e.g., 10 years) is, in medical treatment and 
income loss, in the neighborhood of $50,000 each or about 
$5,000 per patient per year. Multiply this by 10,000, the esti-
mated number of patients in the U.S., and the cost is $50,000,000 
annually! But, since MF is an uncommon disease, the economic 
impact on the population as a whole is probably less than that 
caused by most other lymphomas and leukemias. 
Prevention, Treatment, and Cure 
At the present time, the basic cause of MF is unknown, and 
the pattern of the appearance of the disease in populations 
seems entirely random. Therefore, it seems unlikely that a 
treatment regimen can be developed to prevent MF until more 
fundamental information on its pathogenesis is available. For 
example, if an environmental carcinogen that promotes devel-
opment of MF were demonstrated, then segments of the pop-
ulation at increased risk could be identified and the develop-
ment of prophylactic procedures might be feasible. 
Considerable advances in techniques in the treatment of 
established disease during the past decade have greatly im-
proved the prognosis for most MF patients. Short-term, com-
plete clinical and histological remissions can be anticipated in 
over 90% of patients with MF, provided that the new treatments 
are available and properly used. Long-term complete remissions 
(over 3 years) and even probable cures have been reported for 
some patients who have been treated in the relatively early 
phases of disease (that is, pretumorous intracutaneous disease) 
with total skin electron beam radiation or dilute solutions of 
mechlorethamine for sustained intervals of time. More recently, 
promising short-term beneficial effects on early disease have 
been reported for patients treated with the combination of oral 
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8-methoxypsoralen (a photosensitizer) and long-wave ultravi-
olet light. However, the test of how beneficial these and other 
therapies are for patient survival and cure cannot be made, 
largely because ethical considerations prevent comparable 
groups of untreated patients from serving as controls. 
For patients with advanced intracutaneous or systemic dis-
ease, long-term remissions are uncommon despite the use of 
aggressive chemotherapy, so beneficial in other malignant lym-
phomas. Progress in this area has been hampered by: (1) the 
few studies and limited publications on advanced MF largely 
owing to its infrequent occurrence; (2) lack of knowledge con-
cerning the magnitude of influence that certain systemic drugs 
and other agents have on the disease; (3) reluctance on the part 
of physicians to use systemically administered agents in early 
phases of disease; and (4) lack of knowledge about the biologic 
properties of malignant cells and the body's natural resistance 
to them. Without such knowledge it is impossible to select the 
optimal combinations of therapeutic modalities to control the 
disease. On the other hand, a number of new and adjunct 
therapies (e.g., lymph node and total body photon radiotherapy, 
immunotherapy, leukaphoresis, antithymocyte globulin, etc.) 
give promise of further improvement in treatment of advanced 
and possibly early MF. 
The prospects for future treatment of MF are good for early 
intracutaneous disease and uncertain for later phases of the 
disease. Further progress depends on research outcomes: what 
benefit may accrue from combining established treatments 
(total skin electron beam radiation and topical mechloretham-
ine), from combining less established forms of treatment (pho-
tochemotherapy and leukophoresis), from entirely new thera-
peutic regimens and undiscovered agents in the treatment of 
advanced phases of the disease, and from any untried combi-
nation of these modalities. Experimental efforts of this kind are 
contingent upon adequate support for clinical and basic re-
search, more efficient dissemination of information, and coop-
erative studies. A centralized registry has been established in 
several countries. In the United States a number of institutions 
have formed the "National MF Cooperative Group Study" that 
provides a nucleus for collaboration. The cure rate for MF is 
now 10 to 15%. Progress made in the treatment of lymphoma-
tous disease during the past decade promises a substantial 
increase in this number in the next few decades, particularly 
for patients with early disease. 
Status of Basic Research 
Because of its superficial location and accessibility, MF pro-
vides researchers and clinicians with unique opportunities to 
study a disease representative of the lymphoid cancers and its 
interactions with normal body resistances. Therefore, despite 
its infrequent occurrence in the population, it is a disease of 
considerable theoretical and practical concern, as attested to by 
several national and international seminars recently devoted to 
this disorder. The concepts developed from the study of MF . 
and its variants will undoubtedly apply to other malignant 
lymphomas and cancers. For many years, the nosologic classi-
fication of MF was unsettled. It was uncertain whether MF was 
in essence a reactive benign inflammatory process that, by 
virtue of its chronicity, predisposed to malignant transformation 
or whether it was a malignant neoplasm from the onset. Because 
of histologic similarity to other lymphomas, it was uncertain 
whether MF was a specific disease or merely the cutaneous 
manifestation of some other lymphoma. The confusion was 
confounded by imprecise terminology. 
Pathology. Within the past decade, considerable clinical and 
laboratory evidence has clarified many of these fundamental 
questions. The concept that MF is a malignant process through-
out most of its duration is supported by the following. 
1. A high mortality rate was associated with histologic diag-
nosis and shortened survival with the severity of the disease. 
2. Several autopsy series demonstrated that many organ 
systems were inf'Iltrated by cells morphologically identical to 
the cells involving the skin. 
3. Abnormal cellular DNA and chromosomal patterns fol-
lowed the general pattern of other malignant lymphomas. 
That it is a distinctive lymphomatous disorder is supported 
by such characteristic clinical expressions as the predictable 
progression from the skin to the lymph nodes and then to other 
internal organs, and the distinctive pathologic and cytologic 
features. 
Efforts to uncover cellular markers specific for MF is one 
area of ongoing research in a few institutions. Of special note is 
the finding of cells with deeply convoluted nuclei (best dem-
onstrated by electron microscopy) that are characteristic for 
MF. These distinctive cells are probably one of several cyto-
morphologies that malignant lymphoid cells may assume in 
MF. However, similar cells have been observed in benign der-
matoses and in tissue cultures; consequently, the specificity of 
these convoluted cells as a marker for MF is uncertain. 
The cellular composition of MF lesions tends to undergo 
change with time. "Cell transformation" appears to be a phe-
nomenon in other lymphomas as well. MF lesions composed of 
abnormal cells closely resembling mature lymphoid cells ("Iym-
phocytoid cells") tend to progress with time into lesions com-
posed of cells resembling immature lymphoid cells ("histiocy -
toid cells"). Preliminary data from one center suggest that such 
cellular changes have prognostic importance. It may be that, at 
a given clinical stage, patients with lesions composed of lym-
phocytoid cells respond more favorably to therapy than patients 
with lesions composed of histiocytoid cells. The mechanisms 
involved in and the consequences of cell transformation in MF 
are now under study. 
Immunology. A recent advance in the field of cellular im-
munology has been the definition of distinct subpopulations 
among the normal lymphocyte pool. Among these, human T 
lymphocytes, so named because they differentiate under the 
influence of the thymus gland, have membrane receptors for 
sheep erythrocytes and under experimental conditions will form 
rosettes with the sheep erythrocytes. Normal l' lymphocytes 
are involved in mediating graft rejections, contact allergic re-
action, and many other facets of normal immune function. 
The neoplastic cells of MF have T-cell membrane properties; 
thus MF may now be classified as a T-cell lymphoma. The 
thymus-derived T-cell properties presumably reflect the origin 
of the neoplastic cells in MF and may partly explain why they 
preferentially infIltrate the skin in this disease. Recent obser-
vations have suggested that the epidermis actually promotes 
division of the atypical cells contained within the skin. The 
special interaction of skin epithelium and neoplastic Tlympho-
cytes perhaps is similar to that of skin epithelium and T 
lymphocytes during thymic maturation in utero. The T-cell 
characteristics explain the preferential distribution of meta-
static cells to and within lymph nodes and spleen because these 
organs contain regions normally populated by thymus-derived 
lymphocytes. 
In the study of the interaction of cancer and immunological 
processes, cancers seated in the skin are logical subjects since 
the skin is a sensitive, reactive, and accessable immunological 
organ. The clinical features of MF, such as the tendency for 
some lesions to involute spontaneously, the relatively long 
intracutaneous phase, and the clinical and histologic similarity 
to some inflammatory dermatoses support the concept that 
significant local resistance factors operate to inhibit progression 
of the disease. To augment normal resistance factors and to 
preserve them during the course of treatment are major efforts 
in cancer research today. 
Recent work at several institutions showed that the immu-
nologic status of patients with MF, essentially unimpaired 
during early phases of disease, deteriorated as the disease 
progressed. Skin testing to various topically applied and intra-
I 
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dermal antigens confirmed this immunologic deficiency, as did 
measurements in in vitro experiments: (certain of the blood 
·lymphocyte responses to mitogeneic stimulation of the total 
lymphocyte pool and lymphocyte cell populations, (i.e., Band 
T cells) and of monocyte chemotaxis). These findings seem to 
explain the prevalence of infectious complications in MF pa-
tients. 
The cause-and-effect relationships of these discoveries are 
not known. It seems that the neoplastic T cells of MF retain 
some of the functions of normal T lymphocytes; consequently, 
some of the clinical and laboratory findings ofMF are abnormal 
quantities of cellular products. For example, large quantities of 
macrophage inhibitory factor, presumably produced by the 
neoplastic T cells, have been found in the serum of some 
patients. In animals, infusion of macrophage inhibitory factor 
significantly suppresses the abili ty of the animal to express 
normal immune function, probably by adversely affecting the 
ability of peripheral blood monocytes to mobilize. Could this 
account in part for the observed impairment of monocyte 
chemotaxis and the impaired responses to antigens in skin 
testing of patients with MF? The neoplastic T cell in MF 
promotes antibody synthesis by normal B lymphocytes. Does 
this explain why patients with MF often have elevated levels of 
IGA or IGE serum immonoglobulins that may be particularly 
T cell dependent? These findings indicate that neoplastic T -
cells amplify normal T cell functions, an important implication 
with ramifications extending throughout the entire field of 
human biology. 
Status of Clinical Research 
Many areas of investigation that have direct application to 
treatment were alluded to in the previous paragraphs. The 
recognition and acceptance within the past few decades that 
MF is a specific malignant lymphoma arising within the skin 
has promoted the more aggressive use of well established ther-
apeutic modalities. The current optimism concerning the cur-
ability of the disease is the result of intensive application of 
electron beam radiation and cytotoxic drugs (topical mechlor-
ethamine) to the skin of patients with early phases of the 
disease. At present, several centers are investigating the benefit 
of combining these modalities. 
Several centers are studying the benefits of treatment mo-
dalities, alone and in combination, that appeai· to have a sig-
nificant direct cytotoxic effect on the malignant lymphoid cell: 
other topically applied drugs (nit rosoureas), systemically ad-
ministered drugs (methotrexate-folinic acid), photochemother-
apy (oral psoralen/ longwave ultraviolet light) and radiation for 
systemic disease (lymph node radiotherapy). The recognition 
that MF is a T cell lymphoma has prompted the use, in a 
preliminary fashion, of antithymocyte globulin, which is a some-
what more specific cytotoxin than conventional drugs or radia-
tion. 
At the same time, the recognition that MF patients have 
active immunologic defenses that deteriorate as the disease 
progresses has prompted efforts by some centers to treat with 
agents that augment immunologic reactivity. Topically applied 
antigenic materials can be imposed on lesions of MF to reverse 
and control the disease for variable intervals. Recently, certain 
drugs, such as levamisole, and biologic products, such as t rans-
fer factor, that directly strengthen normal cellular function 
have been administered systemically in exploratory studies to 
determine if direct benefit occurs or if the disease-free interval 
can be lengthened following treatment with other therapies. 
Some centers are mechanically removing the malignant T 
cells from the peripheral blood (Ieukaphoresis) when leukemic 
manifestations are present. This decreases the tumor burden 
substantially and may reinforce other therapies. 
Most of this activity is carried out in less than 10 laboratories 
and o bservations have been made on relatively few patients. 
Often, if technology is available, large numbers of patients with 
MF are not, and vice versa. 
Needs for Additional Basic Research 
The mechanisms behind the conversion of normal lymphoid 
cells to neoplastic cells and the subsequent cellular changes are 
important areas fo r future research in mycosis fungoides. We 
need to determine if the genesis of the disease is related to 
environmental carcinogen exposure, to transformation by an 
oncogenic virus, to chronic immunological stimulation, or to 
some other mechanism. What does the epidermis do in the 
development of the neoplastic cells? What is the relationship of 
the atypical cells with small convoluted nuclei present early in 
the disease to the atypical cells with large vesicular nuclei 
present in the advanced disease state? 
The interrelationship of normal body processes and neoplas-
tic processes is of importance in future research. For example, 
we need to determine what mechanism underlies the occasional 
spontaneous involution of mycosis fungoides lesions. What is 
the fu nction of (and is there any prognostic significance to) the 
collection of eosinophils, plasma cells, and other normal cells 
that frequently are found in cutaneous lesions of MF? Do 
products that are found in neoplastic T-cells, other than "mac-
rophage inhibitory factors, " cause disturbance of normal func-
tions? How do the neoplastic cells cause the inflammatory 
response at the lesions sites? 
We need to fmd out if there is a tumor specific antigen or a 
biochemical marker that is characteristic for MF. What is the 
specificity of the small atypical cell with convoluted nuclei that 
currently is thought to be highly characteristic of MF? Would 
it be possible to diagnose MF earlier by using a cellular marker? 
We need to learn more about the kinetics of cellular prolif-
eration in patients with MF. Specifically, we need to find out 
what the rate of proliferation of malignant cells is in the skin 
and elsewhere. Does this rate of proliferation change with 
duration of the disease? Is it different in variations of the 
disease? 
Whether or not neoplastic cells remain in the skin or circulate 
freely needs to be determined. If they circulate what is their 
fate when they invade other organ systems such as the lymph 
nodes and t he spleen? 
Finally, we need to learn how to propagate neoplastic cells in 
culture and in laboratory animals. Then studies can be done 
with control of any outside influences on growth. 
Needs for Additional Clinical Research 
Many of the unanswered questions about the basic nature of 
the neoplastic cell in MF have direct clinical relevance. With 
present treatment methods the best responses and potential 
cures have been obtained in patients t reated in early phases of 
the disease. Identification of one or more specific cellular 
markers would allow us to detect the disease earlier and, in 
turn, treat eru·lier. 
Information about the cellular composition of MF lesions and 
cellular kinetics may provide prognostic criteria t hat can influ-
ence the choice oftherapeutic regimens. Theoretically, methods 
for measuring the kinetics of cellular proliferation would make 
it possible to select optimal dosages of cytostatic agents on the 
basis of the mitotic rate of malignant cells. If basic studies 
demonstrate that neoplastic cells circulate freely in MF, the 
need for systemically directed therapy would be confirmed. 
There is a need for a more precise definition of the clinical 
vru·iations of MF and development of a uniform staging system 
so that results of treatment in different centers can be com-
pared. Additionally, if we knew how different therapies work 
we might gain insight into mechanisms of the disease. For 
example, does topically applied mechlorethamine affect abnor-
mal cellular proliferation by modifying some proliferative stim-
ulus arising in the overlying epidermis? Studies on mechanisms 
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of drug action could promote our knowledge of the pathophys-
iology of MF. 
3. WARTS AS A DISEASE AND AS A MODEL OF 
VIRAL ONCOGENESIS 
Prevalence and Severity 
Warts are benign skin tumors that generally resolve sponta-
neously. Serological studies indicate that 70% of the population 
has been infected by the wart virus. At any given time about 
10% of children have warts, and almost all persons have warts 
sometime during their life. Usually individuals have only a few 
warts~ but many perso.ns have multiple warts that cause pain or 
that, In the case of children, elicit ridicule by peers. Therefore, 
patients often seek medical care. 
Although warts occur over the entire skin and adjacent 
mucous membranes, certain sites are favored. Warts have been 
named by their appearance and location, i.e., plantar warts on 
the bottom of the foot; flat warts over the arms face and knees' 
anogenital warts, etc. Appearance and locatio~ have some rel~ 
e~an.ce to viral biology. Spontaneous regression generally occurs 
"':'Ithln a 2-ye~r pe~iod, but treatment itself often induces regres-
sIOn. RegreSSIOn IS apparently an immunologic phenomenon. 
Therefore, patients with impaired immunity cannot resolve 
their wart disease, and following immunosuppression therapy 
accompanying renal transplantation and accompanying cancer, 
lymphomas, and leukemia, wart disease becomes a serious 
clinical problem. Some patients develop thousands of warts. 
We are becoming increasingly aware of patients with long-
stand.~g wart disease who finally show evidence of malignant 
transl~lOn. Two well-documented syndromes are (1) giant, non-
resolVing warts, usually anogenital, that eventually show char-
acteristics of invasive squamous cell carcinoma, and (2) lifelong, 
usually familial, flat wart disease with squamous cell carcino-
mas. Recent reports suggest that small, flat genital warts often 
show changes of carcinoma-in-situ. Renal transplant patients 
often have ambiguous wart-carcinoma-tumors. Most of the 
pa~ients with wart disease and carcinoma display some degree 
of Immunologic impairment. 
Estimates of annual cost. Even though only approximately 
8:'0 of office visits to dermatologists are for wart treatment; 
since dermatologists treat only 35% of patients with skin disease 
the annual cost may exceed $200 million in doctors' fees and 
perhaps $20 million in prescribed and over-the-counter medi-
cations. 
Prevention, Treatment, and Cure 
Warts are a contagious disease, and data collected over years 
clearly show greatly increasing prevalence. Plantar warts were 
rare at the turn of the century. In 1900, a Scandinavian der-
matology clinic that saw perhaps 100 new patients with plantar 
warts now sees over 10,000 new plantar wart patients every 
year. The spread of plantar wart disease correlates well with 
public bathin~ ~abits. In a Scottish boarding college, plantar · 
wart~ were ehmmated by preventing swimming in the pool or 
walking In the locker room with bare feet. 
. The prevalence of anogenital wart disease: largely a venereal 
dls~ase, has dramatlc~y mcreased. Changing middle-class mo-
ralIty has greatly contrIbuted to this. Since anogenital warts are 
the ones that most often evidence malignant transition their 
increase warns of a future increase in cancer. ' 
Past treatments for wart disease have been primitive and the 
result~ disappointing. For years we have depended upon de-
structive measures. Unfortunately, destruction (by electrosur-
gery or vesicants like liquid nitrogen) is commonly followed by 
recurrence, necessitating multiple visits to the doctor. Painful 
destructive measures present a special problem with children 
and children are those most commonly involved. ' 
In recent years attention has focused upon the mechanism of 
spontaneous wart regression. It is logical to assume that this 
homeostatic phenomenon involves the immunological system. 
It has been demonstrated that gentle, but irritating, treatment 
with liquid nitrogen or acid solutions over a 12-week period can 
lead to cure. This probably comes about by stimulating the 
same mechanisms involved in spontaneous regression. How-
ever, success in 12 weeks is achieved in only 80% of patients 
with common warts and in only 50% of patients with large 
plantar warts. More than 3 months of treatment is required 
then for many wart patients, a seemingly exorbitant period of 
time considering the nature of the disease. 
There is some indication that the antiviral drugs, iododeoxy-
uridine and 5-fluorouracil, have some efficacy in the treatment 
of wart disease, yet there has been little effort to explore the 
potential of antiviral wart therapy. 
Status of Research 
Basic research in wart disease has taken 2 general directions: 
(1) characterization of wart-associated virion and nonvirion 
antigens and the human immune response to these antigens, 
and (2) molecular studies of viral DNA. Progress has been 
limited. To some extent this is due to our inability to propagate 
human papilloma viruses in tissue culture systems. Neverthe-
less, a good deal of information has evolved. Data now confirm 
the antigenicity of the virion capsid polypeptides, and to some 
extent, the correlation of the host response, both cell-mediated 
and humoral immunity to virion antigens, with spontaneous 
regression . Cell-mediated immunity and complement-fixing IgG 
antibody to virion antigens correlate with wart regression. Non-
virion, wart-associated tissue antigens have been identified. 
These antigens resemble oncofetal antigens. Neither wart spe-
cific transplantation antigens nor papilloma virus T antigen 
have been identified. 
At one time it was thought that warts are caused by a single 
papilloma virus. Molecular and clinical studies have now clearly 
described a multiplicity of human papilloma viruses. Certain 
viruses can be distinguished clinically. Common warts and flat 
warts are caused by different viruses. These viruses differ in 
their susceptibility to bacterial restriction enzymes and their 
ability to crosshybridize. They may also be distinguished by 
immunologic techniques. 
Today's data are being collected by the application of modern 
molecular methods to the human papilloma virus system. The 
investigators are nearly all basic scientists with little clinical 
knowledge or experience; there are very few clinical investiga-
tors active in the field of wart biology. All wart investigation is 
being conducted in less than half a dozen laboratories in the 
United States and Western Europe. 
Needs for Additional Basic Research 
Recently the wart virus has been successfully grown in cul-
ture, although more refined laboratory culture techniques are 
needed. With continued success in culturing the wart virus, 
viral antigens can be isolated and purified. At that time we will 
be able to develop and test antiwart vaccines. 
Technology already exists to answer certain fundamental 
questions concerning warts and should be applied to learn more 
about neoplasia. We need to find out how wart viruses live 
within the skin and what the relationship is of the wart virus to 
the epidermal cells. Are keratinocytes transformed or does the 
virus, in a proliferative cycle, cause the keratinocytes to multi-
ply? Do wart viruses actually cause the eventual malignant 
transformation of warts? How can the relationship of the wart 
virus and the keratinocyte be interrupted? 
Needs for Additional Clinical R esearch 
Methods need to be developed for inducing immunity and 
for hastening wart regression. Studies should be supported to 
evaluate chemical immunotherapy with drugs like DNCB, to 
develop vaccines for wart treatment, and to test the efficacy of 
antiviral drugs. 
Autogenous vaccine therapy for warts was rust tried in 1926; 
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however, nothing definitive can be said about this form of 
therapy. Well-designed clinical studies should be supported to 
determine t he efficacy of autogenous vaccines. 
Studies on the relationship of the papilloma virus and cancer 
are in their infancy. Electron microscopy and molecular biology 
must be used in the study of wart tissue to localize virions and 
the viral genome in tumors undergoing transition to the malig-
• nant state. The Shope system, which uses domestic rabbits that 
are prone to malignant transition of benign papillomas, should 
prove useful to those working in this area. 
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